Tandem Diabetes Care (TNDM) Stock Price, News & Analysis

Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $18.75 to $19.21
• 50-Day Range: $17.89 to $37.06
• 52-Week Range: $17.64 to $53.69
• Volume: 228,019 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $1.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.38
• Consensus Rating: Moderate Buy

Tandem Diabetes Care Stock Analysis - MarketRank™

Tandem Diabetes Care scored higher than 89% of companies evaluated by MarketBeat, and ranked 92nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tandem Diabetes Care has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 11 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tandem Diabetes Care has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tandem Diabetes Care are expected to grow in the coming year, from ($1.68) to ($1.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tandem Diabetes Care is -9.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tandem Diabetes Care is -9.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tandem Diabetes Care has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.94% of the float of Tandem Diabetes Care has been sold short.

Short Interest Ratio / Days to Cover

Tandem Diabetes Care has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Tandem Diabetes Care has recently decreased by 1.54%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tandem Diabetes Care does not currently pay a dividend.

Dividend Growth

Tandem Diabetes Care does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -0.64

Percentage of Shares Shorted

10.94% of the float of Tandem Diabetes Care has been sold short.

Short Interest Ratio / Days to Cover

Tandem Diabetes Care has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Tandem Diabetes Care has recently decreased by 1.54%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.28

News Sentiment

Tandem Diabetes Care has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Tandem Diabetes Care this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

4 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tandem Diabetes Care insiders have bought more of their company's stock than they have sold. Specifically, they have bought $190,949.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.20% of the stock of Tandem Diabetes Care is held by insiders.

TNDM Stock Analysis - Frequently Asked Questions

How have TNDM shares performed this year?

Tandem Diabetes Care's stock was trading at $36.02 at the start of the year. Since then, TNDM stock has decreased by 47.2% and is now trading at $19.0250.
View the best growth stocks for 2025 here.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings results on Wednesday, November, 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.08. The business's revenue was up 31.4% on a year-over-year basis.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care's stock reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Tandem Diabetes Care's major shareholders?

Top institutional investors of Tandem Diabetes Care include Vanguard Group Inc. (11.33%), ArrowMark Colorado Holdings LLC (4.15%), GW&K Investment Management LLC (3.23%) and Fred Alger Management LLC (2.96%). Insiders that own company stock include Kim D Blickenstaff, Dick Allen, Leigh Vosseller, Jean-Claude Kyrillos, John F Sheridan, Kathleen Mcgroddy-Goetz, Christopher J Twomey, David B Berger, Shannon Marie Hansen, Mark David Novara and Rebecca B Robertson.
View institutional ownership trends.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tandem Diabetes Care investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 3/31/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TNDM
• CIK: 1438133
• Web: www.tandemdiabetes.com
• Phone: (858) 366-6900
• Fax: N/A
• Employees: 2,600
• Year Founded: 2006

Price Target and Rating

• Average Stock Price Target: $45.38
• High Stock Price Target: $75.00
• Low Stock Price Target: $22.00
• Potential Upside/Downside: +135.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.61
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-222,610,000.00
• Net Margins: -14.84%
• Pretax Margin: -14.42%
• Return on Equity: -44.19%
• Return on Assets: -11.99%

Debt

• Debt-to-Equity Ratio: 1.29
• Current Ratio: 2.90
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: $940.20 million
• Price / Sales: 1.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.81 per share
• Price / Book: 4.01

Miscellaneous

• Outstanding Shares: 66,473,000
• Free Float: 64,232,000
• Market Cap: $1.28 billion
• Optionable: Optionable
• Beta: 1.45